{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for aminosalicylic root_names_stdName in Standardized Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2023)
Source URL:
First approved in 2014
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
NCT03355846: Phase 4 Interventional Completed Acute Anal Fissure
(2018)
Source URL:
First approved in 2014
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Since its first isolation in 1844, usnic acid has become the most extensively studied lichen metabolite and one of the few that are commercially available. Lichens belonging to usnic acid-containing genera have been used as crude drugs throughout the world. There are indications of usnic acid being a potentially interesting candidate for such activities as anti-inflammatory, analgesic, healing, antioxidant, antimicrobial, antiprotozoal, antiviral, larvicidal and UV protection. However, some studies reported the liver toxicity and contact allergy. Usnic acid reduced the production of Junin virus in infected Vero cells in a dependent dose manner, and 50% inhibition was obtained at an effective concentration (EC50) of 9.9 µM. Regarding the TCRV arenavirus, the effective concentration was 20.6 uM. The selectivity indexes (CC50/EC50) of usnic acid for JUNV and TCRV arenavirus were 6.8 and 3.2, respectively, indicating a specific antiviral activity against these viruses and not just a general consequence of its action on cellular toxicity.
Status:
Possibly Marketed Outside US
First approved in 2014
Source:
NADA141427
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Clodronate (also known as clodronic acid) is a drug used to treat a high level of calcium in the blood caused by changes in the body that happen with cancer. Clodronate is approved in some countries and is sold under trade trade name bonefos for oral use. Bonefos is indicated in the management of osteolytic lesions, hypercalcemia and bone pain associated with skeletal metastases in patients with carcinoma of the breast or multiple myeloma. Bonefos is also indicated for the maintenance of clinically acceptable serum calcium levels in patients with hypercalcemia of malignancy initially treated with an intravenous bisphosphonate. Bonefos forms complexes with divalent metal ions, and therefore simultaneous administration with food, antacids and mineral supplements may impair absorption. It was suggested, that the mechanism of action of clodronate was involved osteoclast apoptosis.
Status:
Possibly Marketed Outside US
Source:
21 CFR 356
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 355
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
Therapytion Nokmosu Sensitive and Dry Hair by Therapytion Co., Ltd.
(2014)
Source URL:
First approved in 2014
Source:
Therapytion Nokmosu Sensitive and Dry Hair by Therapytion Co., Ltd.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Glucuronic acid is a sugar acid that was first identified in urine. It is an intermediate metabolite of the uronic acid pathway. Moreover, glucuronic acid is involved in detoxification of certain drugs and toxins by conjugating with them and forming glucuronides. Glucuronic acid has been found to cause an increase in TLR4-dependent reporter protein expression in a cell line transfected with TLR4 and associated co-signaling molecules, and can cause TLR4-dependent pain in humans.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Glucuronic acid is a sugar acid that was first identified in urine. It is an intermediate metabolite of the uronic acid pathway. Moreover, glucuronic acid is involved in detoxification of certain drugs and toxins by conjugating with them and forming glucuronides. Glucuronic acid has been found to cause an increase in TLR4-dependent reporter protein expression in a cell line transfected with TLR4 and associated co-signaling molecules, and can cause TLR4-dependent pain in humans.
Status:
Possibly Marketed Outside US
First approved in 2014
Source:
NADA141427
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Clodronate (also known as clodronic acid) is a drug used to treat a high level of calcium in the blood caused by changes in the body that happen with cancer. Clodronate is approved in some countries and is sold under trade trade name bonefos for oral use. Bonefos is indicated in the management of osteolytic lesions, hypercalcemia and bone pain associated with skeletal metastases in patients with carcinoma of the breast or multiple myeloma. Bonefos is also indicated for the maintenance of clinically acceptable serum calcium levels in patients with hypercalcemia of malignancy initially treated with an intravenous bisphosphonate. Bonefos forms complexes with divalent metal ions, and therefore simultaneous administration with food, antacids and mineral supplements may impair absorption. It was suggested, that the mechanism of action of clodronate was involved osteoclast apoptosis.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2013
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
First approved in 2013
Source:
NADA141344
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Pradofloxacin (trade name Veraflox) is a 3rd generation enhanced spectrum veterinary antibiotic of the fluoroquinolone class. It was developed by Bayer HealthCare AG, Animal Health GmbH, and received approval from the European Commission in April 2011 for prescription-only use in veterinary medicine for the treatment of bacterial infections in dogs and cats. The primary mode of action of fluoroquinolones involves interaction with enzymes essential for major DNA functions such as replication, transcription, and recombination. The primary targets for Pradofloxacin are the bacterial DNA gyrase and topoisomerase IV enzymes. Reversible association between Pradofloxacin and DNA gyrase or DNA topoisomerase IV in the target bacteria results in inhibition of these enzymes and rapid death of the bacterial cell. The rapidity and extent of bacterial killing are directly proportional to the drug concentration.